Condition: Systemic Sclerosis · Sponsor: Galderma R&D
The main purpose of the study is to investigate the efficacy on cutaneous thickness and the safety of Nemolizumab in adult patients with systemic sclerosis after a 52-week treatment period and to select the optimal dose for this target population.
This description comes directly from the study's public registry record.
Galderma Research and Development · 817-961-5000 · clinical.studies@galderma.com
Always discuss trial participation with your own doctor first.
| Galderma Investigational Site # 8743 | Ann Arbor, Michigan, United States | Recruiting |
| Galderma Investigational Site#7096 | Arlington, Texas, United States | Recruiting |
| Galderma Investigational Site # 6213 | Sankt Gallen, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07047690